Melanoma is an aggressive and often deadly form of skin cancer. Nearly 100,000 adults in the United States will be diagnosed with melanoma this year and approximately seven percent will die from melanoma1. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF. It’s important for patients to get tested and know their BRAF status as it is a key piece of information when evaluating treatment options2.
Results from tests completed under the Know Now Testing Program are available approximately 48 hours after a Quest Diagnostics laboratory receives a sample, which could lead to timely and optimal treatment decisions. To access the Know Nowprogram and its no-cost testing, healthcare professionals should visit http://www.knownowbraf.com and download the BRAF Test Request Form.
‘At Novartis, we know that understanding potential mutations is critical for melanoma patients and their doctors to make informed treatment decisions,’ said Ameet Mallik, Executive Vice President and Head, US, Novartis Oncology. ‘We recognize the barriers that often keep patients from being tested. That’s why we’re empowering the melanoma community with this Know Now Testing Program.’
People diagnosed with stage III or stage IV melanoma can ask their doctor about BRAF testing and the Know Now Testing Program to access its no-cost testing benefit.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.